ROGERS CORP
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $810.8 | $830.1 | $908.4 | $971.2 | $932.9 |
| Operating income | -$45.0 | $24.9 | $85.3 | $144.4 | $117.2 |
| Net income | -$61.8 | $26.1 | $56.6 | $116.6 | $108.1 |
| Cash Flow Statement | |||||
| Free cash flow | $71.1 | $71.0 | $74.4 | $12.7 | $53.3 |
| Share repurchases | $52.4 | $19.8 | $0.0 | $25.0 | $0.0 |
Shares outstanding 17.9M · Free float 95.6%
Annual filing data through FY ended December 31, 2025; float as of September 17, 2026.
Coverage
September 23, 2026
Biotech Pipeline
Petrelintide: amylin development now has a major partner
September 23, 2026
Biotech Pipeline
Petrelintide and enicepatide enter a separate combination study
September 23, 2026
Biotech Pipeline
Obesity development: mechanisms and treatment patterns, not a league table
September 23, 2026
Biotech Pipeline
Enicepatide: a renamed program enters a broader obesity portfolio
September 23, 2026
Biotech Pipeline
Enicepatide: diabetes-population evidence adds a new chapter